Goldman Sachs Group Inc Inhibrx, Inc. Transaction History

Goldman Sachs Group Inc

$605 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $7.32 Million - $8.84 Million	223,360 Added 145.82%	376,540 $13.2 Million
Q4 2023 Feb 13, 2024	SELL	$14.5 - $38.0 $91,190 - $238,982	-6,289 Reduced 3.94%	153,180 $5.82 Million
Q3 2023 May 14, 2024	BUY	$15.75 - $26.31 $99,051 - $165,463	6,289 Added 4.11%	159,469 $2.93 Million
Q3 2023 Nov 14, 2023	SELL	$15.75 - $26.31 $1.43 Million - $2.39 Million	-90,948 Reduced 36.32%	159,469 $2.93 Million
Q2 2023 May 14, 2024	BUY	$16.96 - $27.82 $1.28 Million - $2.09 Million	75,236 Added 42.95%	250,417 $6.5 Million
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $1.28 Million - $2.09 Million	75,236 Added 42.95%	250,417 $6.5 Million
Q1 2023 May 14, 2024	BUY	$18.45 - $27.14 $54,630 - $80,361	2,961 Added 1.72%	175,181 $3.31 Million
Q1 2023 May 11, 2023	BUY	$18.45 - $27.14 $54,630 - $80,361	2,961 Added 1.72%	175,181 $3.31 Million
Q4 2022 May 14, 2024	BUY	$20.18 - $33.33 $341,364 - $563,810	16,916 Added 10.89%	172,220 $4.24 Million
Q4 2022 Feb 13, 2023	BUY	$20.18 - $33.33 $341,364 - $563,810	16,916 Added 10.89%	172,220 $4.24 Million
Q3 2022 May 14, 2024	BUY	$11.58 - $24.73 $866,844 - $1.85 Million	74,857 Added 93.05%	155,304 $2.79 Million
Q3 2022 Nov 10, 2022	BUY	$11.58 - $24.73 $866,844 - $1.85 Million	74,857 Added 93.05%	155,304 $2.79 Million
Q2 2022 May 14, 2024	SELL	$8.52 - $25.26 $619,685 - $1.84 Million	-72,733 Reduced 47.48%	80,447 $914,000
Q2 2022 Aug 15, 2022	SELL	$8.52 - $25.26 $545,552 - $1.62 Million	-64,032 Reduced 44.32%	80,447 $914,000
Q1 2022 May 16, 2022	BUY	$19.89 - $43.18 $445,794 - $967,793	22,413 Added 18.36%	144,479 $3.22 Million
Q4 2021 Feb 14, 2022	SELL	$26.75 - $46.02 $1.14 Million - $1.95 Million	-42,467 Reduced 25.81%	122,066 $5.33 Million
Q3 2021 Nov 10, 2021	BUY	$25.18 - $37.81 $4.14 Million - $6.22 Million	164,533 New	164,533 $5.48 Million

Others Institutions Holding INBX

# of Institutions

Shares Held

18.6K

Call Options Held

Put Options Held

Credit Suisse Ag Zurich, V8

18.6K
Shares

$270,990
0.0% of portfolio

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $570M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account